Novo Nordisk’s Wegovy Weight Loss pills have seen an increase in popular meteors.
nuphoto | Getty Images
Novo Nordisk On Wednesday, he said he would offer weight loss pills at less than half the usual price through a new online consumer pharmacy.
Cash Pay offers are available to millions of patients without insurance coverage for a blockbuster injection. We aim to make Wegovy available to more people, but we aim to ensure patients use branded medications instead of the inexpensive composite copycat that exploded in popularity during the recently resolved Novo Nordisk drug shortage.
A pharmacy called Novocare allows patients to pay $499 per month in cash for weekly drugs. Wegovy’s regular price before insurance and other rebates is almost $1,350 per month.
The site also allows Wegovy prescriptions to be sent directly to the patient’s home through our specialist pharmacy partners. NovoCare also offers refill reminders and access to live support from the company’s case manager, among other patient support services.
“Patients and prescribers alike have another option to reduce the costs of high-quality pens and provide convenient access to all doses of real FDA approved Wegovy,” said Dave Moore, Executive Vice President of US Business and Global Business Development.
In particular, the company said “in the near future” that it could extend Wegovy’s new savings offer to cash-paid patients using traditional retail pharmacies, and pay lower prices as well.
The Danish drugmaker’s move follows similar strategies from its major rivals Eli Lily. The two companies are fighting to dominate the so-called GLP-1 market. It mimics certain intestinal hormones to suppress appetite and regulates blood glucose levels.
In January 2024, Eli Lilly launched its own online consumer pharmacy, LillyDirect, to allow patients to access Zepbound, a weight loss drug.
This website allows eligible patients to obtain prescriptions and provide home delivery via telehealth providers. More recently, Lillydirect has begun offering Zepbound in single-dose vials that are half or more than the usual $1,000 monthly price.
In recent months, the Food and Drug Administration has declared a shortage of both Zepbound and Wegovi in ​​the US. That decision prevents certain combined pharmacies from creating unapproved versions of injections.
Novocare helps patients “avoid the “significant risks that the compounding market can pose,” as well as respected organizations, medical experts and FDA experts warn,” Novo Nordisk said in a statement.
